全文获取类型
收费全文 | 260899篇 |
免费 | 25944篇 |
国内免费 | 16323篇 |
专业分类
耳鼻咽喉 | 2288篇 |
儿科学 | 3554篇 |
妇产科学 | 3274篇 |
基础医学 | 28248篇 |
口腔科学 | 4517篇 |
临床医学 | 35164篇 |
内科学 | 35184篇 |
皮肤病学 | 3013篇 |
神经病学 | 12152篇 |
特种医学 | 8950篇 |
外国民族医学 | 111篇 |
外科学 | 23763篇 |
综合类 | 47994篇 |
现状与发展 | 59篇 |
一般理论 | 26篇 |
预防医学 | 20633篇 |
眼科学 | 6628篇 |
药学 | 29420篇 |
334篇 | |
中国医学 | 17840篇 |
肿瘤学 | 20014篇 |
出版年
2024年 | 1073篇 |
2023年 | 4124篇 |
2022年 | 10702篇 |
2021年 | 13459篇 |
2020年 | 10440篇 |
2019年 | 8517篇 |
2018年 | 8867篇 |
2017年 | 8697篇 |
2016年 | 7980篇 |
2015年 | 12249篇 |
2014年 | 15050篇 |
2013年 | 14819篇 |
2012年 | 21388篇 |
2011年 | 22895篇 |
2010年 | 15727篇 |
2009年 | 12608篇 |
2008年 | 15586篇 |
2007年 | 14856篇 |
2006年 | 13938篇 |
2005年 | 12771篇 |
2004年 | 8458篇 |
2003年 | 7614篇 |
2002年 | 6218篇 |
2001年 | 5120篇 |
2000年 | 4953篇 |
1999年 | 4633篇 |
1998年 | 2668篇 |
1997年 | 2712篇 |
1996年 | 2107篇 |
1995年 | 1972篇 |
1994年 | 1766篇 |
1993年 | 1060篇 |
1992年 | 1380篇 |
1991年 | 1217篇 |
1990年 | 989篇 |
1989年 | 922篇 |
1988年 | 824篇 |
1987年 | 673篇 |
1986年 | 495篇 |
1985年 | 427篇 |
1984年 | 207篇 |
1983年 | 167篇 |
1982年 | 101篇 |
1981年 | 137篇 |
1980年 | 83篇 |
1979年 | 111篇 |
1978年 | 54篇 |
1977年 | 56篇 |
1976年 | 42篇 |
1974年 | 48篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
53.
Assessment of Myocardial Infarct Size by Three‐Dimensional and Two‐Dimensional Speckle Tracking Echocardiography: A Comparative Study to Single Photon Emission Computed Tomography
下载免费PDF全文
![点击此处可从《Echocardiography (Mount Kisco, N.Y.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
54.
冯莹 《中国实用外科杂志》2020,40(5):531-536
易栓症是外科围手术期静脉血栓栓塞症(VTE)的防治重点。对于接受手术的止凝血障碍病人,需要谨慎评估VTE的个体风险,同时兼顾手术和麻醉的性质、出血障碍类型和严重程度、年龄、体重指数(BMI)、血栓形成史、恶性肿瘤和其他高危共患病。VTE风险应与已知出血障碍病人使用抗凝相关的出血风险平衡。实验室检查有助于发现和判断血栓与出血的病因,对病人的止凝血代偿能力作出评估,并对抗凝药物的合理使用提供依据。对上述病人,建议术后不常规使用药物预防血栓,尤其是血友病病人,但围手术期因子替代和止血药物的过度应用仍存在导致血栓的风险。使用低分子肝素(LMWH)和直接口服抗凝剂前应评估肾小球滤过率。当血小板计数<50×109/L,LMWH短期减量应用可能相对安全,监测抗Хa水平可用于调整中重度血小板减少症病人LMWH的剂量。主要消化道出血停止和重新使用华法林应至少相隔7 d。对于高血栓栓塞风险和术后高出血风险病人,术后当晚和术后第1天减量应用直接口服抗凝剂是一种可取的做法。 相似文献
55.
Chih-Wei Hsu Sheng-Yu Lee Yao-Hsu Yang Liang-Jen Wang 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2020,23(10):653
BackgroundGeneric antidepressants are approved on the market based on evidence of bioequivalence to their brand-name versions. We aimed to assess whether generic antidepressants exert equal effectiveness as their brand-name counterparts for treating patients with depressive disorders.MethodsIn a nationwide, population-based cohort in Taiwan from 1997 through 2013, patients with a diagnosis of a depressive disorder aged between 18 and 65 years who were new users of antidepressant drugs were classified into either the brand-name group or the generic group. All patients were followed up until medication discontinuation or the end of the study period. We assessed the risk for hospitalization as a primary outcome and augmentation therapy, daily dose, medication discontinuation, or switching to another antidepressant as secondary outcomes.ResultsA total of 277 651 brand-name users (35.8% male; mean age: 41.2 years) and 270 583 generic users (35.8% male; mean age: 41.0 years) were divided into 10 different antidepressant groups (fluoxetine, sertraline, paroxetine, escitalopram, citalopram, venlafaxine, mirtazapine, moclobemide, imipramine, and bupropion). We found that patients treated with the generic form of sertraline, paroxetine, escitalopram, venlafaxine, mirtazapine, and bupropion demonstrated significantly higher risks of psychiatric hospitalization (adjusted hazard ratios ranged from 1.20–2.34), compared to their brand-name counterparts. The differences between brand-name antidepressants and their generic counterparts in secondary outcomes varied across different drugs.ConclusionsCompared to most generic antidepressants, brand-name drugs exhibited more protective effects on psychiatric hospitalization for depressive patients. These findings could serve as an important reference for clinicians when encountering patients with depressive disorder. 相似文献
56.
目的分析成人血液系统恶性肿瘤患者接受强烈化疗后中性粒细胞减少性肠炎(NE)的发生率、危险因素及预后情况。方法收集2004至2013年接受化疗的1804例血液系统恶性肿瘤患者,记录患者血常规、凝血检测和血液生化检测结果,并记录患者年龄、性别、原发病、既往化疗次数、既往化疗方案中是否使用阿糖胞苷、临床症状、肠壁厚度、中性粒细胞最低计数、中性粒细胞缺乏持续时间、NE的治疗方法和预后等,探讨NE起病诱因、临床特征、腹部B超特点、症状的预后意义及化疗药物对发病的影响等。结果1804例患者中226例(12.5%)化疗后合并NE,化疗后10~19d起病,中位起病时间为化疗后第14天。发生NE后26例患者死亡,病死率11.5%。化疗药物包括阿糖胞苷、临床症状≥4项、中性粒细胞缺乏持续超过7d以及B超下肠壁厚度≥10mm的患者病死率相对较高。结论NE是接受强烈化疗的血液系统肿瘤患者的严重的并发症,发生NE后患者病死率较高。 相似文献
57.
58.
59.
To evaluate the anthropometric indexes in subjects with varicocele compared to controls and the incidence of varicocele in different body mass index (BMI) groups for the purpose of exploring the association between varicocele and anthropometric indexes. A comprehensive literature search was conducted by using PubMed, MEDLINE, EMBASE databases and Cochrane Library up to February 2019. A systematic review and meta‐analysis was conducted by STATA, and Newcastle–Ottawa Scale was utilised for assessing risk of bias. Ultimately, 13 articles containing seven case–control studies and six cross‐sectional studies with 1,385,630 subjects were involved in our study. Pooled results demonstrated that varicocele patients had a lower BMI (WMD = ?0.77, 95% CI = ?1.03 to ?0.51) and a higher height than nonvaricocele participants, especially in grade 3 varicocele patients. Subgroup analyses showed that normal BMI individuals had a higher risk of varicocele than obese or overweight individuals and a lower risk than underweight individuals. In conclusion, this study indicates that varicocele patients have a lower BMI and a higher height than nonvaricocele participants. Moreover, men with excess bodyweight have a lower incidence of varicocele compared to normal weight or underweight people. That is to say, high BMI and adiposity protect against varicocele and high BMI is associated with a decreased risk of varicocele. 相似文献
60.